UK Teacher Who Lied About Lymphoma Banned From Classroom

A 44 year old primary school teacher at Park Junior School, in Shirebrook, Mansfield, Nottinghamshire, in England has been banned from teaching after it was revealed that for four years she had been lying to colleagues, students and parents about having mediastinal large B-cell lymphoma. She received considerable support from those around her.

Nicola Lynne Hibberd had gone to great lengths to perpetuate the lie, including creating phony letters from physicians claiming she had been diagnosed with late-stage non-Hodgkin's.

She recently appeared before a Teaching Agency panel in Coventry and was found guilty of unacceptable professional conduct. She gave no explanation for her choice to mislead those around her, nor did she present any potentially mitigating factors to explain it.

Despite that, many are speculating that she used the ruse in order to score for herself a substantial amount of time off from teaching.

Hibberd was exposed when her head teacher, Steve Hewitt-Richards, became suspicious of a letter from one of her alleged doctors and came to believe it probably had been copied from the Macmillan Cancer website, one of the biggest and most influential in the UK.

Hewitt-Richards pursued things further by contacting Nottingham University Hospitals Trust, where she had claimed to be receiving her care. They informed him that the patient was not in their database.

Despite the ban, she could re-apply to teach after five years.

Source: Daily Mail

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap